Study of Thymoglobulin to Arrest Type 1 Diabetes (START)
Thymoglobulin is an antibody preparation that is commonly used to treat and prevent organ transplant rejection. The START trial aims to determine whether Thymoglobulin treatment can halt the progression of newly diagnosed type 1 diabetes when given within 3 months of diagnosis. This study is for people aged 12-35 years old.
A Phase I Trial of IL-2 and Sirolimus in Recent-onset Type 1 Diabetes Mellitus
This is a phase I trial in individuals who have been diagnosed with
type 1 diabetes within the previous 3-48 months. The study is testing
whether two immune system modifying drugs are safe when used in
combination and if they have immune altering effects that indicate they
can halt the progression of type 1 diabetes progression.
Cytokine production in blood leukocytes of prediabetic children and effect of intranasal insulin
This study is being performed in collaboration with the Finnish Diabetes Prediction and Prevention project that is studying individuals in various stages of prediabetes and who will receive intranasal insulin as part of a secondary prevention trial. The ITN is funding the support of additional laboratory studies that hope to identify biomarkers that can predict the onset of type 1 diabetes, and to learn more about the natural history of the disease.
Inducing Remission in Type 1 Diabetes with Alefacept (T1DAL)
Abatacept and Cyclophosphamide Combination: Efficacy and Safety Study (ACCESS) for Lupus Nephritis
This study is for people with systemic lupus who have developed complications in their kidneys, called 'lupus nephritis'. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophosphamide therapy by itself.
Pilot Study to Determine the Immunogenicity of Immucothel® and Oral Tolerance Induction with Biosyn Native KLH in Healthy Subjects
The purpose of this study is to determine whether Immucothel, a Keyhole Lymphocyte Antigen (KLH) product, can trigger an immune response when ingested orally and create "oral tolerance" to KLH. If not, Immucothel will be tested with another agent to enhance the immune response.
